WT1 protein expression in childhood acute leukemia

American Journal of Hematology

Volumn 83, Issue 5, 2008, Pages 382-386

  Kerst, Gunter ^a   Bergold, Nina ^a   Gieseke, Friederike ^a   Coustan Smith, Elaine ^b   Lang, Peter ^a   Kalinova, Marketa ^c   Handgretinger, Rupert ^a   Trka, Jan ^c   Müller, Ingo ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CELL LINE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FLOW CYTOMETRY; GENETIC CODE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; BLOOD CELLS; BONE MARROW CELLS; BURKITT LYMPHOMA; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, WILMS TUMOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; NEOPLASM PROTEINS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RNA, MESSENGER; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 42949092269     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21123     Document Type: Article

References (43)

1. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992;6:405-409.
2. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997;89:1405-1412.
3. Trka J, Kalinova M, Hrusak O, et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 2002;16:1381-1389.
4. Cilloni D, Saglio G. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol 2004;112:79-84.
5. Ostergaard M, Olesen LH, Hasle H, et al. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - Results from a single-centre study. Br J Haematol 2004;125: 590-600.
6. Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999;13:393-399.
7. Cilloni D, Gottardi E, Messa F, et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 2003;21: 1988-1995.
8. Garg M, Moore H, Tobal K, Liu Yin JA. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 2003;123:49-59.
9. Barragan E, Cervera J, Bolufer P, et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004;89:926-933.
10. Boublikova L, Kalinova M, Ryan J, et al. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 2006;20:254-263.
11. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071-3079.
12. Uzunel M, Ringden O. Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation. Bone Marrow Transplant 2004;33:47-52.
13. Ogawa H, Tamaki H, Ikegame K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003;101: 1698-1704.
14. Cilloni D, Gottardi E, De Micheli D, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002;16: 2115-2121.
15. Mailander V, Scheibenbogen C, Thiel E, et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004;18:165-166.
16. Tsuboi A, Oka Y, Udaka K, et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 2002;51:614-620.
17. Kerst G, Kreyenberg H, Roth C, et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol 2005;128:774-782.
18. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometr 1999;38:139-152.
19. Neale GA, Coustan-Smith E, Pan Q, et al. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 1999;13:1221-1226.
20. Dworzak MN, Fritsch G, Panzer-Grumayer ER, et al. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance. Leuk Lymphoma 2000;38:295-308.
21. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998;352:1731-1738.
22. Pongers-Willemse MJ, Seriu T, Stolz F, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 1999;13:110-118.
23. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 1998;12: 2006-2014.
24. Campana D. Applications of cytometry to study acute leukemia: in vitro determination of drug sensitivity and detection of minimal residual disease. Cytometry 1994;18:68-74.
25. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995;85:1416-1434.
26. Lucio P, Gaipa G, van Lochern EG, et al. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 concerted action investigation of minimal residual disease in acute leukemia: International standardization and clinical evaluation. Leukemia 2001;15:1185-1192.
27. Menssen HD, Siehl JM, Thiel E. Wilms tumor gene (WT1) expression as a panleukemic marker. Int J Hematol 2002;76:103-109.
28. Kletzel M, Olzewski M, Huang W, Chou PM. Utility of WT1 as a reliable tool for the detection of minimal residual disease in children with leukemia. Pediatr Dev Pathol 2002;5:269-275.
29. Magyarosy E, Varga N, Timar J, Raso E. Follow-up of minimal residual disease in acute childhood lymphoblastic leukemia by WT1 gene expression in the peripheral blood: the Hungarian experience. Pediatr Hematol Oncol 2003;20:65-74.
30. Van Dijk JP, Knops GH, Van De Locht LT, et al. Abnormal WT1 expression in the CD34-negative compartment in myelodysplastic bone marrow. Br J Haematol 2002;118:1027-1033.
31. Baird PN, Simmons PJ. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp Hematol 1997;25:312-320.
32. Ellisen LW, Carlesso N, Cheng T, et al. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J 2001;20:1897-1909.
33. Menssen HD, Renkl HJ, Rodeck U, et al. Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia. Int J Cancer 1997;70:518-523.
34. Menssen HD, Renkl HJ, Rodeck U, et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995;9:1060-1067.
35. Hossain A, Nixon M, Kuo MT, Saunders GF. N-terminally truncated WT1 protein with oncogenic properties overexpressed in leukemia. J Biol Chem 2006;281:28122-28130.
36. King-Underwood L, Pritchard-Jones K. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998;91:2961-2968.
37. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9:1783-1786.
38. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96:2691-2696.
39. Chen JS, Coustan-Smith E, Suzuki T, et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 2001;97:2115-2120.
40. Campana D, Coustan-Smith E. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002;15:1-19.
41. Gabert J, Beillard E, van der Velden V, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe against cancer program. Leukemia 2003;17:2318-2357.
42. Beillard E, Pallisgaard N, van der Velden V, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - A Europe against cancer program. Leukemia 2003;17:2474-2486.
43. Kreuzer KA, Saborowski A, Lupberger J, et al. Fluorescent 5′-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias. Br J Haematol 2001;114:313-318.